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ANALYSIS OF LONG-TERM OPIOID PRESCRIBING PRACTICES IN CANCER 
PATIENTS AT A PEDIATRIC TERTIARY INSTITUTION 
JENNY JAN 
ABSTRACT 
Introduction: Pain is common in cancer. Pain can present at the time of diagnosis 
or it can develop during treatment. Cancer-related chronic pain is often treated 
with long-term (3 or more consecutive refills) opioid prescriptions.  Opioids are a 
controlled substance and are thus regulated at the federal, state, and local levels.  
Objectives: The first goal of this study is to examine Boston Children’s Hospital’s 
general compliance with federal, state, and local opioid prescribing policies. The 
second goal of this study is to distinguish cancer patients requiring long-term 
opioids from non-cancer patients requiring long-term opioids. 
Methods: This study was a retrospective chart review using summative 
qualitative content analysis. This is the process where content is grouped into 
themes and then is further quantified within each theme. 
Results: Documents required to ensure compliance with opioid prescribing 
regulations at the local level are not always well documented. These include the 
Long-Term Opioid Agreement and the risk evaluation of opioid misuse and abuse 
using one of several tools annually. At Boston Children’s Hospital (BCH), the 
CRAFFT (car, relax, alone, forget, friends, trouble) questionnaires are used for 
this purpose. State policies require that, if a patient is not seen at least once 
every 6 months, physicians must document explicitly why a clinic visit was not 
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possible. These reasons are never clearly listed within the medical record. 
Additionally, data shows that cancer patients using long-term opioids tend to be 
younger (mean age 14.4) than non-cancer patients (mean age 26.7). Cancer 
pain can present either at diagnosis, during treatment, or be present during both. 
Where n=16 cancer patients, 62.53% experienced pain both at diagnosis and 
during treatment, 25% experienced pain only during treatment, and 12.5% 
experience pain only at diagnosis. Finally, data also show that anxiety and 
comorbidity are common, 34.6% of n=29 patients in both cancer and non-cancer 
patients using long-term opioids. 34.6% of patients experienced comorbidities of 
either anxiety or depression. 
Conclusions: Despite these discrepancies with documentation, review of patients 
on long-term opioids revealed those with complex and painful medical conditions 
generally had valid reasons to require long-term opioids.  Therefore, there is no 
evidence that BCH prescribers are involved in any sort of inappropriate opioid 
prescribing. Finally, no meaningful conclusions were drawn from data regarding 
pain score and weight because of inconsistencies in electronic medical record 
documentation in these areas.   
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INTRODUCTION 
 
 Opioids are prescription medications that are used to treat pain. 
They act on opioid receptors in the brain, spinal cord, and organs, thereby 
decreasing the body’s perception of pain. For this reason, they are 
commonly used as analgesics and have long been used in the treatment 
of acute and terminal pain.  
About 10 million people worldwide are diagnosed with cancer each 
year (IASP, 2015). Pain is common amongst these patients and is either 
present at the time of diagnosis or develops throughout the course of the 
disease. Approximately 25% to 30% of patients with cancer report pain at 
the time of diagnosis (Pharo and Zhou, 2005), and about 70% to 80% 
develop pain over the course of their disease (Mercadante and Fulfaro, 
2005). Cancer pain has many etiologies. Tumor infiltration, for example, 
can cause cancer-related pain. Additionally, cancer treatments themselves 
can cause pain. Patients may experience post-surgery pain, 
chemotherapy-induced neuropathic pain, anti-estrogen therapy-related 
musculoskeletal pain, or radiotherapy-induced pain. Unrelieved cancer 
pain can have devastating effects on a patient, such as functional 
impairment, immobility, social isolation, emotional and spiritual distress, 
psychological stress, and ultimately, a reduced quality of life (Pergolizzi et 
al. 2014 and IASP, 2015). 
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While the practice of long-term opioid use in the treatment of 
chronic non-cancer pain is still under study, its use in chronic cancer pain 
is widely accepted. Opioids are both inexpensive and highly effective in 
treating cancer-related pain (WHO, 2015). The World Health Organization 
(WHO) has developed some useful guidelines in prescribing opioids for 
cancer pain. When these WHO guidelines are followed, they have been 
shown to provide effective pain control in 90% of patients (Pharo and 
Zhou, 2005). The WHO has developed a 3-step model for adults, where a 
patient with persisting or increasing pain is first given non-opioid 
medications. If pain still remains, then the patient is given an opioid 
prescription for mild/moderate pain. If this still does not provide enough 
pain relief, then the patient is given an opioid prescription for 
moderate/severe pain (WHO, 2015). For pediatric cancer patients, on the 
other hand, the WHO has adapted a 2-step model for opioid prescribing. 
Pediatric patients with mild/moderate pain should be given ibuprofen or 
paracetamol. Pediatric patients with moderate/severe pain should be 
given strong opioids, with morphine being the drug of choice (WHO, 
2012). 
Common childhood cancers include leukemia, lymphoma, bone 
sarcomas, brain tumors, and neuroblastomas. These can cause diffuse 
bone and joint pain or headaches throughout the course of the disease. 
During the course of their treatment, pediatric cancer patients can also 
  
 
 3 
suffer from neuropathic pain, which results from injury to the nervous 
system, as a result of damage caused by treatment (chemotherapy, 
radiation, etc.), or a tumor disrupting nerves or the spinal cord. 
Additionally, pain can result from treatment complications such as 
mucositis or infection. Treatment related cancer pain is common and is 
commonly managed with opioids.  
Oral codeine, morphine, oxycodone, hydromorphone, fentanyl, and 
methadone are the opioid analgesics commonly prescribed for pain 
management. Of these, morphine is one of the most commonly prescribed 
and is used for moderate to severe cancer pain (IASP, 2009). Morphine is 
generally the fist opioid agent physicians will prescribe to patients with 
cancer pain. If dose-limiting side effects arise, then hydromorphone or 
fentanyl can be used (IASP, 2014). Finally, Methadone has a long half-life 
and is considered a long-acting drug. It is often prescribed when patients 
build tolerance to their shorter-acting opioid analgesics. 
In general, opioid prescribing in the United States has increased 
steadily in the past decade (Benyamin, 2008). In 2012, 259 million 
prescriptions were written for painkillers. This is enough for every 
American adult to have a prescription for opioids (CDC, 2014). As 
prescription rates have risen, deaths from prescription drug overdose have 
also followed suit and are now the leading cause of unintentional death 
(CDC, 2014).  Opioid prescriptions are commonly written upon hospital 
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discharge and there is evidence that some of these legally administered 
drugs are being diverted for non-medical use (Manchikanti and Singh, 
2008). It is unlikely, though, that hospital prescribers are writing enough 
prescriptions to supply the entire national opioid problem, even though 
some hospital prescribing rates can run as high as 72% among patients 
being admitted for nonsurgical reasons (Herzig, 2014). Studies have 
shown that hospitals with higher opioid prescription rates have a high risk 
of a severe opioid-related adverse event occurring per patient (Herzig, 
2014). 
In the United States, approximately 90% of chronic pain patients 
are receiving opioids (Benyamin, 2008). Patients receiving pain treatment 
with long-term opioids are at a high risk for diagnoses of drug abuse, drug 
dependence, and drug addiction (Fishbain, 1992). Of this subset of 
patients, a small percentage is at risk for abuse or addiction, while a larger 
percentage is at risk for displaying aberrant drug-related behaviors and 
illicit drug use (Fishbain, 2008).  Additionally, higher dosages of opioid 
medications indicate greater risks for opioid misuse (Bohnert et al., 2011) 
and overdose (Dunn, 2010). 
Patients with a history of drug or alcohol abuse (especially with 
previous drug or driving while under the influence convictions) are more 
likely to commit opioid misuse (Ives, 2006). For this reason, patients with a 
history of substance abuse should be closely monitored and followed for 
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signs of misuse, abuse, or diversion if opioids are prescribed (Ives, 2006). 
For example, Boston Children’s Hospital has developed a validated 
questionnaire that evaluates a patient’s history of drug or alcohol abuse. 
This questionnaire – the CRAFFT screening questions (Figure 2 and 3) – 
is designed to help physicians identify patients with higher risks of opioid 
misuse, abuse, or diversion. The CRAFFT questionnaire is so named 
because of its assessment six areas of behavior and how they are 
influenced by a patient’s drug use: car, relaxation, being alone, 
forgetfulness, friends, and getting into trouble. 
 In addition to risk of abuse or addiction, there are also many side 
effects associated with opioid use. The two most common side effects are 
constipation and nausea, which can last throughout the entire duration of 
opioid use (Benyamin, 2008). Other major side effects include sedation, 
dizziness, vomiting, constipation, and respiratory depression (Benyamin, 
2008). Some of the less common side effects also include delayed gastric 
emptying, hyperalgesia (at high doses), immunologic dysfunction, 
hormonal dysfunction, muscle rigidity, and myoclonus (Benyamin 2008). 
The side effects and risk of abuse/addiction associated with opioids keep 
long-term use a relevant matter of debate. 
Doctors who prescribe opioids have a responsibility to follow up 
with their patients. They have an obligation to monitor patients to ensure 
that the benefits of opioid use in the treatment of long-term pain outweigh 
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the costs.  Physicians use a variety of methods when overseeing their 
patients on long-term opioid therapy. One technique simply does not 
provide enough information. Urine toxicology testing and behavioral 
assessment together are better able to identify patients with inappropriate 
drug-taking behavior than either method alone (Katz, 2003). In addition to 
urine drug screening, most long-term opioid guidelines throughout the 
nation also agree that specific attentions should be paid to upper dosing 
thresholds, drug-drug and drug-disease interactions, and use of risk 
assessment tools and treatment agreements when monitoring patients on 
long-term opioids (Nuckols, 2014). Examining patients regularly and 
asking them questions about their level of pain, opioid use and function 
provide a lot of information. Getting the perspective of parents and 
caregivers on function is very important.  
Opioids are a controlled substance regulated by federal, state, and 
local laws. The Controlled Substances Act (CSA) is the overarching law 
that regulates opioids (and other controlled substances) at the federal 
level. The CSA mandates that opioids can only be dispensed with a 
written prescription from a practitioner (FDA, 2011). There are also 
separate laws that govern opioid prescribing practices at the state level. 
The state of Massachusetts, for example, requires that all opioid 
prescriptions be manually signed and that separate prescriptions are 
written for each controlled substance (Patrick, 2010). Additionally, opioid 
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prescriptions are only valid for 30 days after their issue date, and cannot 
be filled for more than a 30-day supply at a time (Patrick, 2010). Finally, 
Massachusetts’s law states that when prescribing opioids over a long 
period of time, physicians must see the patient at least once every six 
months, or otherwise write a note in the medical records explaining why 
this might be impractical (Patrick, 2010). 
Opioid prescribing is also locally regulated. Tertiary institutions 
have their own policies that differ slightly from one another. Boston 
Children’s Hospital in Massachusetts, for example, requires long-term 
opioids be prescribed electronically for ease of tracking. Additionally, 
patients or parents/caregivers and the prescriber are required to sign the 
Boston Children’s Hospital Controlled Substance Agreement (Figure 1) 
annually. Physicians are also required to assess a patient’s level of risk 
annually using the CRAFFT questionnaire (Figure 2 and 3) (BCH, 2012a). 
The assessed level of risk is used to determine frequency of clinical 
evaluations and urine screenings. Patients who are determined to be low 
risk are required to have an in person evaluation with the prescribing 
physician at least every four months (BCH, 2012a). Patients who are 
determined to be of moderate risk are required to have an in person 
evaluation with the prescribing physician at least every one month (BCH, 
2012a). Subsequently, patients with high risk are required to have more 
frequent urine toxicology screens. 
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Literature in pediatric long-term opioid use is scarce. Most of the 
strategies used in dealing with children on long-term opioids are derived 
from information provided in adult literature. There are no randomized 
controlled trials that deal with breakthrough pediatric cancer pain. 
(Friedrichsdorf, 2014). The limited data available in this area of research 
indicates that pediatric cancer pain is “common, under assessed, and 
undertreated” (Friedrichsdorf, 2014). Additionally, most hospitals do not 
have chronic pain teams that can adequately address non-palliative long-
term opioid use.  
 Boston Children’s Hospital has a Pain Treatment Service that was 
founded in 1986. The Pain Treatment Service draws together multiple 
disciplines in order to provide “treatment and support for acute and chronic 
pain in children and young adults” (BCH, 2005). Boston Children’s 
Hospital’s Pain Treatment Service is part of the Department of 
Anesthesiology, Perioperative, and Pain Medicine and, at the time, was 
the first program of its kind (BCH, 2005). The Pain Treatment Service 
provides both inpatient consultations as well as an outpatient clinic. In 
terms of opioid prescribing, the inpatient branch of the Pain Treatment 
Service monitors perioperative, acute pain opioid dosing, and other 
general inpatient pain medication needs. The outpatient branch of the 
Pain Treatment Service, on the other hand, is involved in the overall pain 
management of patients with chronic pain. 
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 The objective of this study is two-fold. The first goal is to examine 
Boston Children’s Hospital’s compliance with federal, state, and local 
opioid prescribing regulations. The second is to better characterize cancer 
patients who are using long-term (3 or more consecutive refills) opioids. 
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Figure 1. BCH Long-Term Opioid Agreement. This document outlines the responsibilities of both the 
prescribing clinician and the patient’s (or guardian’s) responsibilities involved in receiving opioid 
prescriptions. For patients on long-term opioids, this document should be signed yearly in order to guarantee 
safe and effective use of these medications. (BCH, 2012b). 
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Figure 2. BCH CRAFFT screening tool self assessment. This document is designed as a questionnaire 
survey for patients to fill out annually. Part A of the document is designed to assess the patient’s history of 
substance abuse, and Part B, should the patient present with any illegal drug use, is designed to assess 
patient behavior associated with drug use (BCH, 200b). 
  
 
 
1
2
 
Figure 3. BCH CRAFFT screening interview. These documents are designed for clinic personnel 
conducting a patient interview and should be updated annually. Part A of the CRAFFT interview asks about 
patient history of substance abuse. If a patient does report a history illegal drug use, then Part B questions 
are used to clarify the patient’s behaviors during and around drug use. The second page is a set of 
instructions for the clinic personnel conducting the patient interview (BCH, 2009a).
The CRAFFT Screening Interview 
 
Begin: “I’m going to ask you a few questions that I ask all my patients. Please 
be honest. I will keep your answers confidential.” 
  
Part A   
During the PAST 12 MONTHS, did you:    No Yes 
1. Drink any alcohol (more than a few sips)? 
(Do not count sips of alcohol taken during family or religious events.) 
  
2. Smoke any marijuana or hashish?   
3. Use anything else to get high?   
(“anything else” includes illegal drugs, over the counter and 
prescription drugs, and things that you sniff or “huff”)   
 
For clinic use only: Did the patient answer “yes” to any questions in Part A? 
No  Yes  
  
Ask CAR question only, then stop Ask all 6 CRAFFT questions 
   
Part B No Yes 
1. Have you ever ridden in a CAR driven by someone (including yourself) who 
was “high” or had been using alcohol or drugs? 
  
2. Do you ever use alcohol or drugs to RELAX, feel better about yourself, or fit 
in? 
  
3. Do you ever use alcohol or drugs while you are by yourself, or ALONE?   
4. Do you ever FORGET things you did while using alcohol or drugs?   
5. Do your FAMILY or FRIENDS ever tell you that you should cut down on your 
drinking or drug use? 
  
6. Have you ever gotten into TROUBLE while you were using alcohol or drugs?   
 
CONFIDENTIALITY NOTICE: 
The information recorded on this page may be protected by special federal confidentiality rules (42 CFR Part 
2), which prohibit disclosure of this information unless authorized by specific written consent. A general 
authorization for release of medical information is NOT sufficient for this purpose. 
© CHILDREN’S HOSPITAL BOSTON, 2009. ALL RIGHTS RESERVED. 
Reproduced with permission from the Center for Adolescent Substance Abuse Research, CeASAR, Children’s Hospital 
Boston. (www.ceasar.org)  
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METHODS 
 
 
 Algorithms were used to analyze retrospective prescription data 
and identify patients using long-term (at least 3 consecutive refills) opioids 
during the 2014 calendar year. These algorithms were also used to collect 
basic patient demographics, the number of prescriptions written during the 
specified time frame, and the original order date and time, the order 
mnemonic, and the prescriber. 
 Once patients on long-term opioids were identified, a retrospective 
chart review (using Boston Children’s Hospital’s electronic medical record 
system in Powerchart) was conducted to collect relevant data. Data 
collection included patient demographics, clinical characteristics, co-
morbidities, clinical course, prescribing practices, and compliance with 
controlled substance agreements. “Demographics” includes information 
such as age, gender, race, ethnicity, language, and weight. “Clinical 
characteristics” includes information such as the type of pain, the average 
pain score, the lowest documented pain score, and the highest 
documented pain score. “Clinical course” includes information such as 
important visit dates (to the pain service, oncology clinic, etc.), any 
complications during a visit, length of time the patient has been on long-
term opioids, and whether or not prescription order dates correspond with 
a visit with the prescriber. “Prescriptions” includes the patient’s current 
prescriptions, length of time on a specific drug, and number of prescribers 
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for each drug in the same time frame. Finally, “Compliance with controlled 
substance agreements” includes the patient’s documented level of risk, 
any safeguards established to address risk, date of signed Boston 
Children’s Hospital controlled substance agreements, and dates of urine 
tests. Visual representation of each of the above described categories is 
presented below in Table 1. Finally, co-morbidities were also listed for 
each patient. This was essentially a list of the various diagnoses a patient 
had. 
Demographics 
Age 
Gender 
Race 
Ethnicity 
Weight 
Language 
 
Clinical Characteristics 
Type of Pain 
Level of Acuity 
Lowest Pain Score 
Highest Pain Score 
Non-Cancer, Pain at Diagnosis, Pain During Treatment, or Both ? 
 
Clinical Course 
Relevant Visit Dates 
Complications 
Length of Time on Long-Term Opioids 
Prescription Date 
Corresponding Visit? Yes/No 
 
Table 1: Data collection categories. These are the categories and 
subcategories for which data was collected during this chart review. 
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Prescriptions 
Drug 
Method of Delivery 
Number of Prescribers 
Concentration 
Current Dose 
Date Started 
 
Compliance with Controlled Substance 
Regulations 
Level of Risk 
Safeguards Addressing Risk 
Date of First Long-Term Opioid Agreement 
Date of Most Recent Long-Term Opioid Agreement 
Signed Yearly? Yes/No 
Kept Follow-Up Visits? Yes/No 
Date of Urine Screening 
 
Table 1 continued. Data collection categories. 
 
 The information obtained from this small subset of patients on long-
term opioids was used in a summative qualitative content analysis 
(Solodiuk, 2014). This process includes grouping content into themes then 
further quantifying the numbers within each theme. The data analysis was 
a non-directed process and themes were identified only during the review 
of the data. 
 Additionally, several guidelines were established to help direct data 
collection. For example, the decision was made to look through a patient’s 
entire history with the Pain Treatment Service, instead of just clinic notes 
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from the 2014 calendar year. This was also the case for any other relevant 
clinics involved in monitoring the patient’s pain management.  
When examining compliance with opioid prescribing regulations, 
follow up visits or communications with the prescribing physician had to be 
within 2 weeks of the date the prescription order was sent in to the 
pharmacy. If visits or communications occurred outside of this two-week 
time frame, then the prescription date was considered to have no 
associated clinic visit or communication. In addition, the mathematical 
average between all documented pain scores was used when 
documenting the level of acuity of the patient’s pain. Pain scores were 
collected from every clinical note under the Boston Children’s Hospital 
Service responsible for a patient’s pain management. Both the lowest and 
highest documented pain scores across all visits were collected as well. 
There were several incidences where, out of all of a patient’s clinic visits, 
only one pain score was provided. If the patient self-reported this single 
pain score as the level of pain he/she feels “on average”, then it was 
recorded as the average level of acuity. In any other cases where only one 
pain score was recorded, level of acuity (Table 1) was not calculated 
because it would not have been an accurate representation of the 
patient’s average. Instead, the single pain score was recorded as either 
the lowest or highest pain score as reported by the patient.  
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Age is an important demographic characteristic in describing 
patients that are on long-term opioids. When collecting data, the patient’s 
current age (at the time their chart was reviewed) was recorded. If a 
patient was deceased at the time of review, their age at death was 
recorded. Secondly, when documenting patient weight, patients heavier 
than 50 kg, or greater than 14 years old, had to have a recent weight 
documented within the last two years. Patients between 25 kg and 50 kg, 
had to have a documented weight within the last year. Finally, patients 
less than 25 kg, had to have a documented weight within the last six 
months. If these criteria were not met, then patient weight was considered 
“not documented”. 
Finally, cancer patients were specifically grouped into “at 
diagnosis”, “during treatment”, or “both”. These categories refer to the 
timing of pain presentation. Patients who experienced pain at diagnosis, 
but were documented to have “good pain relief” from their opioid regimen, 
experienced no new pain, and consistently “denied pain” during clinic 
visits were assumed to have had no pain from their treatment. Thus, these 
patients were classified in the “at diagnosis” group. Additionally, patients 
who did develop treatment-related pain, but did not experience pain at, or 
prior to, diagnosis were classified in the “during treatment category”. 
Finally, patients that had pain both at diagnosis and pain due to treatment 
were classified in the “both” category.  
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RESULTS 
Retrospective chart review of patients on long-term opioids has 
provided insight into the opioid prescribing practices at Boston Children’s 
Hospital. More specifically, the study has also allowed us to examine the 
institution’s compliance with federal, state, and local opioid prescribing 
regulations, as well as to identify specific characteristics of cancer patients 
in need of long-term opioids. 
The Commonwealth of Massachusetts requires that patients taking 
opioids must be seen by their physician every 6 months or have explicit 
explanation why this is not possible. For patients on long-term opioids not 
seen at least every six months, there was never an explicit statement of 
why these visits did not occur. Upon detailed examination of the medical 
record though, one is able to infer why these visits were not possible. For 
example, the patient had advanced muscular dystrophy and traveling to 
and from Boston Children’s Hospital would be extremely difficult.  
 Local opioid prescribing regulations specific to Boston Children’s 
Hospital state that patients must complete the CRAFFT questionnaire 
(Figure 2 and 3) to help determine level of risk. The level of risk 
established by the CRAFFT questionnaire determines the frequency of 
clinic visits and urine screenings a patient needs. Chart review of patients 
on long-term opioids shows no CRAFFT questionnaire on file for any 
patient. Furthermore, level of risk was never formally documented in the 
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medical records and there was no record of urine toxicology screens for 
opioids for any of the patients. 
 Additionally, Boston Children’s Hospital policies state that patients 
must sign the “Opioid Long-Term Agreement” (Figure 1) annually. 
Extensive chart review showed that most patients do not have any such 
signed agreement in their electronic medical records (ERM). For patients 
that did have at least one signed Opioid Long-Term Agreement on file, 
very rarely was the agreement updated annually, and documentation was 
sporadic at best. Out of a total of 29 patients reviewed, and four patients 
that had at least one signed Boston Children’s Hospital Opioid Long-Term 
Agreement, only one was a cancer patient being followed through the 
Dana Farber Cancer Institute (DFCI) Oncology Clinic. The remaining three 
had non-cancer diagnoses, one of whom demonstrated full compliance 
with local policy on signing the BCH Opioid Long-Term Agreements 
annually. Thus, out of a total of 29 patients reviewed, only one patient 
demonstrated compliance in regards to the Opioid Long-Term Agreement. 
 Physicians working in the Pain Service were not the only opioid 
prescribers. Often times, other clinics and services within Boston 
Children’s Hospital were responsible for prescribing and following up with 
patients on long-term opioids. For cancer patients, the Dana Farber 
Cancer Institute Oncology Clinic prescribed and followed up with patients. 
For patients with very complex healthcare needs, or requiring home 
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ventilation, the CAPE (Critical Care Anesthesia Perioperative Extension 
and Home Ventilation) program was often the source of opioid prescription 
and follow-up. Finally, for patients involved in palliative care program, the 
PACT (Pediatric Advanced Care Team) service was often responsible for 
opioid prescribing and patient follow-up. 
 
 A total of 29 patients were identified for long-term opioid use (>3 
consecutive refills) in 2014.  55% of these patients had a primary 
diagnosis of cancer, and 45% had diagnoses other than cancer. Cancer 
diagnoses were limited to leukemia, Ewing’s sarcoma, neuroblastoma, 
retinoblastoma, and osteosarcoma. These are all consistent with the 
accepted common childhood cancers. All cancer patients identified within 
this study received opioid prescriptions, and subsequent follow-up through 
the DFCI Oncology Clinic. 
 
A. Ages of Patients 
 In general, cancer patients tend to be younger chronic opioid users 
than non-cancer patients (Table 2). The mean age of a cancer patient 
taking long-term opioids is 14.4 years, whereas the mean age of non-
cancer patients requiring long-term opioids is 26.7 years.  Additionally, 
within the cohort of patients using long-term opioids, the youngest cancer 
patient is 3 years old and the oldest is 25 years old. Non-cancer patients, 
on the other hand, occupy a larger age range, with the youngest being 5 
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years old, and the oldest being 65 years old at the time this chart review 
was conducted. 
 
Ages of Cancer 
Patients (years) 
Ages of Non-cancer 
Patients (years) 
3 5 
4 6 
7 10 
7 17 
10 23 
13 28 
13 30 
13 31 
14 31 
17 31 
17 32 
20 38 
21 65 
22 
24 
25 
Mean=14.4 Mean=26.7 
 
Table 2. Ages of cancer vs non-cancer patients. The ages 
documented are the patients’ ages at the time their charts were reviewed. 
If a patient was deceased at the time of chart review, then their age at 
death was documented. 
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B. Weights of Patients 
Cancer patients on long-term opioids weigh more, on average, than 
non-cancer patients on long-term opioids (Table 3). The mean weight of 
cancer patients is 54.6 kg, and the mean weight of non-cancer patients is 
39.7 kg. This is the opposite of what is expected, given the mean ages of 
cancer and non-cancer patients.  Cancer patients on long-term opioids are 
younger, on average, and therefore mean weight is expected to be less 
than that of non-cancer patients. This issue is discussed in greater detail 
in the “Discussion” section of this paper. 
Of the patients included in this study (n=8), 27.6% did not have a 
recently documented weight within the ERM (Figure 4). Of these, only one 
was a cancer patient. This means that 87.5% of patients with 
undocumented weights were non-cancer patients, and only 12.5% were 
cancer patients. Additionally, of the 21 patients that did have recently 
documented weights (Figure 4), only 28.6% were non-cancer patients, as 
opposed to 71.4% that were cancer patients. In general, the DFCI 
oncology clinic was much better at consistently documenting patient 
weight in the ERM than other services were. 
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Weights of Cancer 
Patients (kg) 
Weights of Non-Cancer 
Patients (kg) 
13.3 14.9 
14.8 31.8 
20.5 34.9 
21.6 52.5 
30 45 
33.2 59.2 
43.4 
45.4 
67.5 
73.7 
77.9 
84 
87.8 
97.8 
108.4 
Mean=54.6 Mean=39.7 
 
Table 3. Documented weights of cancer vs non-cancer patients. 
Patients heavier than 50 kg, or greater than 14 years old, had to have a 
weight recorded within the last two years. Patients between 25 and 50 kg, 
had to have a documented weight within the last year. Finally, patients 
less than 25 kg, had to have a documented within the last six months. If 
these criteria were not met, then a patient’s weight was considered “not 
documented”. 
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Figure 4. ERM weight documentation status by patient type. There 
were a total of eight patients with undocumented weights in their ERM. 
Seven of these patients were non-cancer patients, and only one was a 
cancer patient. There were only six non-cancer patients with documented 
weights, as opposed to 15 cancer patients with recently documented 
weight. 
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C. Timing of Pain Presentation 
 Cancer pain can be present at the time of diagnosis, develop during 
treatment, or both.  Of the 16 cancer patients in this study, 62.53% 
experienced pain both at diagnosis and during their treatment, 25% 
experienced pain due to treatment only, and 12.5% experienced pain at 
diagnosis only (Figure 5). 
 
 
 
Figure 5. Timing of cancer pain presentation.  Of the total of 16 cancer 
patients requiring long-term opioids for pain management, one had pain 
only at diagnosis, four had pain only during treatment, and 11 had pain 
both at diagnosis and due to treatment. 
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 Patients experiencing pain during treatment mostly suffered from 
mucositis and neuropathy due to their chemotherapy and/or radiation 
course. There were also a few patients who suffered from steroid-related 
pain. There were also some instances where donor transplants and 
subsequent graft versus host disease caused significant, lasting pain in 
patients. In general, cancer patients can experience several different types 
of pain with different etiologies throughout the course of their disease. For 
example, there was a cancer patient who suffered from generalized 
muscle aches and pains due to steroid withdrawal as well as oral pain 
associated with mucositis. 
 
D. Average Level of Acuity 
 Pain acuity is measured on a scale of 0 – 10, with 0 representing 
no pain, and 10 representing the worst pain a patient has ever felt. The 
mean level of pain acuity cancer patients experience is 5.2/10. The mean 
level of pain acuity of non-cancer patients is 5.5/10 (Table 4). 
Unfortunately, no meaningful conclusions were drawn from these values 
due to inconsistencies in ERM documentation. This is further discussed in 
the “Discussion” section of this paper. 
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Average Level of Acuity: 
Cancer Pain Non-Cancer 
Pain 
3 1.23 
3.75 5.5 
4.5 5.67 
5.33 6.7 
6 8.5 
7   
Mean=5.2 Mean=5.5 
 
Table 4. Average level of acuity: Cancer vs Non-cancer pain. Each 
number on this graph represents the average level of acuity calculated for 
a single patient. The “average level of acuity” for each patient represents 
the average pain score across all documented pain scores. These scores 
are on a 0-10 scale. 
 
 
E. Presence of Anxiety and Depression 
Anxiety and depression were very common co-morbidities with 
chronic pain. Of the 29 total patients in this study, 34.6% had issues with 
anxiety or depression (Figure 6). Of these patients, 40% had issues with 
both anxiety and depression. Additionally, of the 34.6% of patients with co-
morbidities of anxiety or depression, 40% of had primary diagnoses other 
than cancer, and 60% had primary diagnoses of cancer (Figure 7). 
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Figure 6. Number of patients with co-morbidities of anxiety, 
depression, both, or neither. Of the 29 patients in this study, three 
patients experienced anxiety in addition to their primary diagnosis. Three 
patients experienced depression, four patients experienced both anxiety 
and depression, and 19 had no issues with neither anxiety nor depression. 
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Figure 7. Co-morbidity of anxiety or depression: Cancer vs Non-
cancer patients. A total of 10 patients were identified to have co-
morbidities of anxiety and/or depression. Of these patients, six patients 
had primary diagnoses of cancer, and four patients had primarily non-
cancer diagnoses. 
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DISCUSSION 
 Detailed examination of patients using long-term opioids at Boston 
Children’s Hospital shows opioids being prescribed appropriately to 
patients with valid reasons for long-term pain and the need for opioids. 
Diagnoses included to leukemia, Ewing’s sarcoma, neuroblastoma, 
retinoblastoma, and osteosarcoma often with metastatic disease.  
It is important to note that documentation did not often include the 
requirement of assessment of risk, pain intensity function or opioid 
agreement.  
The CRAFFT questionnaire (Figures 2 and 3) and urine screening 
are both used to assess a patient’s level of risk while on long-term opioids. 
Risk assessment is especially important in preventing diversion of opioids 
for non-medical use. Three different categories of risk – low risk, moderate 
risk, and high-risk child – are important in categorizing a patient’s potential 
for opioid misuse, abuse, or diversion. A fourth category – high risk parent 
– is used in the case of a minor requiring long-term opioids, and assesses 
parent or guardian potential for misuse, abuse, or diversion of opioids 
prescribed to the patient. Without risk level assessment and urine 
screenings, evaluation of whether or not compliance visits were scheduled 
at appropriate intervals for each patient was not possible. Additionally, 
lack of documentation in these areas makes it difficult to identify patients 
(or guardians) at risk for opioid misuse, abuse, or diversion. More 
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specifically, occasional but consistent urine screenings would be helpful in 
identifying patients who are, or have, developed habits of misuse.  
Boston Children’s Hospital’s Opioid Long-Term Agreement (Figure 
1) is important because it outlines both the prescribing physician’s and the 
patient’s responsibilities throughout the duration of opioid use. The 
absence of a signed Opioid Long-Term Agreement within this chart review 
could imply that many of the patients are not fully aware of the 
responsibilities involved in carrying out a long-term opioid prescription. 
They may be unaware of the expectations their physicians have of them, 
as well as the legal aspects of their prescription. The Family Education 
Sheet of Frequently asked Questions about Opioid Treatment for Long-
Term Pain (Figure 8) provides additional information about opioid use. 
This document is extremely informative, and should be something patients 
(and their parent/guardians) are given in tandem with the Opioid Long-
Term Agreement. These two documents together provide patients with 
sufficient information about their opioid prescription. 
 
 
  
 
 
3
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Figure 8. Long-term opioid family education sheet. This document lists some of the frequently asked 
questions (FAQ) about opioid use. It is meant to provide patients and their families with important 
information regarding opioids (BCH, 2013). 
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Figure 8. continued. Long-term opioid family education sheet. (BCH, 2013). 
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There were only four patients in total that had at least one Opioid 
Long-Term Agreement signed. These results could represent a lack of 
education in general about BCH opioid prescribing policies. If this is the 
case, then efforts to increase awareness could be made. These efforts 
could include, for example, hospital staff-wide email memos, or exposure 
at mandatory department meetings.  
It is not known why the CRAFFT questionnaire, urine screening, 
and Opioid Long-Term Agreement were not documented. It may be that 
current templates for documentation in the medical record do not guide 
clinicians to include this information. It is also possible that further 
education of prescribers on local prescribing policies, which have been put 
in place for the safety of patients, is needed. When prescribers are 
unaware of opioid prescribing policies, their patients may end up 
uninformed of the consequences of and their responsibilities in managing 
long-term opioid prescriptions.  Finally, it is also a possibility that clinicians 
are uncomfortable having conversations with patients and families about 
opioid addiction, misuse and abuse. 
While the documentation supporting opioid prescriptions is 
seriously lacking within the ERM at Boston Children’s Hospital, there is no 
evidence of inappropriate opioid prescribing. Many of the patients within 
this study are very sick and have extremely complex healthcare needs. 
For example, a patient with Duchenne’s Muscular Dystrophy who is 
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virtually bed-ridden would have a very difficult time getting to and from the 
Pain Treatment Service outpatient clinic. In this, and other similar 
instances, there is little to no risk of patient opioid misuse, abuse, or 
diversion.  
Boston Children’s Hospital is a pediatric tertiary institution. This 
means that a patient’s parent or guardian is often heavily involved in, or 
directly responsible for, making medical decisions and home care of the 
patient (depending on patient age and circumstance). While younger 
patients themselves may not be at risk for opioid misuse, abuse, or 
diversion, there is always the possibility that the parent or guardian is high 
risk for these behaviors. Thus, prescribers or other clinic staff should be 
sure to assess both patients and parents/guardians using the CRAFFT 
screening questions (Figures 2 and 3) for any high-risk drug behavior. 
For patients that can report pain, the level of pain intensity is self-
reported using the 0-10 Numeric Rating Scale, where 0 represents no 
pain, and 10 represents the worst pain the patient has ever experienced. 
The mean level of iacuity of cancer patients documented in the medical 
record is 5.2/10. This is much higher than the mean pain scores 
documented at Boston Children’s hospital in 2010, 2011, and 2012 where 
the scores were 1.46, 1.34, and 1.3, respectively (Solodiuk, 2014). This 
discrepancy can be attributed to scarce ERM pain score documentation 
for patients on long-term opioids. It must be understood that the numbers 
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calculated from this chart review may or may not represent the actual 
experience of the patient because pain scores were not consistently 
documented in the EMR.  
Also, because of inconsistencies in EMR documentation, it is 
difficult to distinguish whether or not long-term prescriptions are even 
helping patients with chronic pain. Pain is a subjective experience, which 
is what makes pain intensity scores so important. Pain scores 
operationalize and quantify a patient’s pain experience into terms that 
physicians can understand and assess. They also provide a baseline 
physicians can use to gauge the efficacy of pain management. Ideally, a 
patient presenting with new chronic pain would report higher pain scores 
initially and lower pain scores after starting their long-term opioid therapy. 
Without proper and consistent documentation of pain scores, it becomes 
difficult to assess whether or not long-term opioids are an effective form of 
pain management. Thus, pain score documentation is important for 
physicians to practice good pain management. 
Within this study, 25% of cancer patients developed pain 
throughout the course of their treatment and 12.5% were already 
experiencing pain at the time of diagnosis (Figure 5). This differs from 
previous literature, which reports that approximately 25% to 30% of 
patients with cancer experience pain at the time of diagnosis (Pharo and 
Zhou, 2005), and about 70% to 80% develop pain over the course of their 
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disease (Mercadante and Fulfaro, 2005). While the specific values are 
different, the studies do agree that a smaller percentage of patients 
experience pain at diagnosis than the percentage of patients that develop 
pain throughout their course of treatment. Specific differences may be due 
to the small sample size n=29 of this particular study, or the fact that this 
study is based on a pediatric population, and the previous studies were 
based on adult populations. Larger studies with pediatric populations 
across multiple geographic locations would yield more accurate results not 
only in terms of the timing of cancer pain presentation, but also in terms of 
understanding pediatric cancer pain. 
Weight is an important demographic value with many clinical 
implications. More specifically, weight plays a crucial role in medication 
dosage. This is especially true in pediatrics, where drugs are primarily 
dosed according to body weight or body surface area. Therefore, 
inconsistent ERM weight documentation can pose issues in opioid 
prescribing. If a patient has gained weight, but such weight gain is not 
documented, then prescribers would not know to increase opioid doses. 
This would ultimately result in undertreated pain, which can have 
implications greater than the patient’s immediate discomfort. As discussed 
earlier, unrelieved pain can lead to functional impairment, immobility, 
social isolation, emotional and spiritual distress, psychological stress, and 
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ultimately, a reduced quality of life (IASP, 2015 and Pergolizzi, et al. 
2014). 
The DFCI Oncology Clinic was much more consistent with 
documenting patient weight than other BCH services. Only 6.3% of all 
cancer patients had an undocumented weight. This is small compared to 
the 53.8% of all non-cancer patients that had no documented weight 
(Figure 4). This result is very likely attributed to the fact that oncology 
patients are very closely and frequently monitored due to the nature of the 
cancer treatment itself. Nausea and vomiting are very common side 
effects of chemotherapy and radiation therapy. Both of these can lead to 
sudden weight loss, which would be detrimental to a patient. There are 
also certain cancer drugs that can lead to sudden weight gain, which could 
put the patient at risk for medical problems such as obesity and diabetes 
mellitus type II. Aside from concerns with the general health of the patient, 
the DFCI Oncology Clinic must monitor weight for medication dosing 
purposes. Both chemotherapy overdosing and underdosing can be deadly 
for a patient due to the cytotoxic nature of the drug and the 
aggressiveness of cancer itself, respectively. Thus, cancer is a disease 
that requires close monitoring. This is most likely why the DFCI Oncology 
Clinic practices more reliable weight documentation in the ERM. 
Comorbidities of anxiety and depression were very common with 
patients suffering from chronic pain and subsequent long-term opioid use. 
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Many of these patients had multiple health issues and very complex care. 
Advanced care needs seemed to decrease the patient’s quality of life and 
thus, it almost comes as no surprise that anxiety and depression were 
common in this subset of patients. 
 Finally, the algorithm used to identify patients for this study was 
applied to four different quarters within the 2014 calendar year. This 
means that a separate list of patients on long-term opioids was generated 
four different times. Thus, patients that took long-term opioids throughout 
the entire calendar year should have appeared on this list for all four 
quarters. The chart review process showed that this was not the case. 
There were several instances where patients experiencing chronic pain 
were definitely taking long-term opioids beyond the single quarter they 
were listed under. There were just a few patients that were carried through 
all four quarters, but it was clear that more patients should have been. 
This does imply some degree of error within the algorithm and suggests 
that there may be more patients using long-term opioids than initially 
reported. Modification of the algorithm for future studies would hopefully 
resolve this issue. 
 Given the results of this study, it is evident that Boston Children’s 
Hospital should take efforts to increase awareness of their opioid 
prescribing policies. This study has also highlighted several 
inconsistencies within the ERM documentation. It is important for the care 
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of the patient that ERM documentation is reliable and up to date. For this 
reason, clinical staff should be made aware of the inconsistencies in 
weight and pain score documentation. Both of the above-described issues 
must be addressed in order for physicians to practice good pain 
management. Therefore, Boston Children’s Hospital should consider 
hospital staff-wide email memos and/or mandatory staff briefings to 
increase awareness about these issues. 
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